Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15219673 | 0.85 | GABRA1 (0.47) | GAAALDH1A1ACHEHTR6 | |
| SCHEMBL1748276 | 0.81 | GAA (0.42) | GAAALDH1A1LMNAACHEHTR6 | |
| SCHEMBL9928940 | 0.80 | LMNA (0.39) | LMNATP53HTT | |
| SCHEMBL14655676 | 0.79 | CYP2D6 (0.49) | ACHECYP2D6ADRA2AADRA1A | |
| SCHEMBL27703893 | 0.77 | KDM4E (0.43) | GAAALDH1A1LMNAHTR6 | |
| SCHEMBL27703895 | 0.77 | ERN1 (0.42) | GAAALDH1A1LMNAACHEHTR6 | |
| SCHEMBL1541914 | 0.77 | ACHE (0.59) | GAAALDH1A1LMNAACHE | |
| SCHEMBL5053454 | 0.76 | ALDH1A1 (0.37) | GAAALDH1A1LMNATP53HTT | |
| SCHEMBL1748248 | 0.76 | LMNA (0.55) | ALDH1A1LMNATP53HTTCYP2D6 | |
| SCHEMBL20868996 | 0.76 | LMNA (0.55) | ALDH1A1LMNATP53HTTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604021-B2 | Substituted arylamine compounds and methods of treatment | BECKER OREN (IL) | 2013-12-10 | — | — | US | disclosed |
| CN-101203500-B | Substituted arylamine compounds and their use as 5-HT6Use of modulators | GALENEA CORP | 2013-08-21 | — | — | CN | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| CN-101203500-A | Substituted arylamine compounds and their use as 5-HT6Use of modulators | EPIX DELAWARE INC (US) | 2008-06-18 | — | — | CN | disclosed |
| EP-1856075-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | Epix Delaware, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006081332-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | EPIX DELAWARE, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | HTR6, HTR2A, HTR3B | GAA 1586/4885ALDH1A1 1488/4885LMNA 4313/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | GAA 1586/4885ALDH1A1 1488/4885LMNA 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.